Chugai Seiyaku Kabushiki Kaisha

Ajinomoto Co., Ltd.

Asahi Kasei Kogyo Kabushiki Kaisha

Etsuro Ogata

Koichi Endo

Kyoji Ikeda

Yuzuru Eto

Hiroshiro Shibai

Itaru Kojima

Toshiaki Tsunenari

Etsuro Onuma

Shigeru Shioya

Kiyoshi Kurokawa

Hidemi Saito

Makoto Shiozaki

Yumiko Azuma

Yasuo Totsuka

Akiko Kishida

Shunya Uchida

The present invention provides an agent for ameliorating low vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof; and an agent for ameliorating a symptom caused by a decrease in vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

Agents for ameliorating low vasopressin level

A method for inhibiting bone metastasis of a malignant tumor in a patient who has a cancer excluding breast cancer comprises administering to said patient an effective amount of a compound of the formula (III):wherein Rrepresents a C1-C10 alkyl group substituted by one or more hydroxyl groups is provided.

Malignant tumor metastasis inhibitors

Monitoring method of renal lesions without clinical signs

Pharmaceutical compositions containing the polypeptides BUF-3, BUF-4 and BUF-5 have hypoglycemic activity. BUF-3 is a homodimer of monomer A shown in FIG. 1. The monomer has a molecular weight of 16.+-.1 kd. BUF-4 is a heterodimer of monomer A and monomer B (FIG. 2). These products can be produced by cell culture of malignant leukemia cells or by recombinant DNA engineering.

Method of reducing blood sugar levels using a hypoglycemic agent

Growing community of inventors

Tokyo, Japan

Etsuro Ogata